Physician profile
Joseph Clemente
NPI 1164425435
$1,996.16
in general payments reported to CMS, 2019-2025
30 companies · $80.79 in 2025
The $80.79 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $743 · 2021: $402 · 2022: $399 · 2023: $28.76 · 2024: $23.48 · 2025: $80.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $133.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $266.25 | 2019-2022 | |
| Amarin Pharma, INC. | $199.48 | 2019-2022 | |
| Novo Nordisk INC | $191.53 | 2019-2022 | |
| Pfizer INC. | $163.16 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $141.22 | 2019-2022 | |
| Amgen INC. | $110.74 | 2021-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.79 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $79.56 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.03 | 2019-2022 | |
| Glaxosmithkline, LLC. | $65.88 | 2020 | |
| Boston Scientific Corporation | $65.15 | 2020 | |
| Davol INC. | $59.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $59.45 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.22 | 2019-2022 | |
| Phadia US INC. | $48.10 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $46.26 | 2022 | |
| Lilly USA, LLC | $42.15 | 2019-2022 | |
| Daiichi Sankyo INC. | $35.06 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.37 | 2019-2020 | |
| Sanofi Pasteur INC. | $26.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.48 | 2024 | |
| Abbott Laboratories | $22.00 | 2020 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Lucid Diagnostics INC. | $16.00 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.99 | 2021 | |
| Esperion Therapeutics, INC. | $14.47 | 2020 | |
| Astellas Pharma US INC | $13.94 | 2019 | |
| Abbvie INC. | $13.86 | 2023 | Qulipta |
| Sanofi-Aventis U.S. LLC | $13.49 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Clemente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.